Clinical Trials Logo

Electronic Cigarette Use clinical trials

View clinical trials related to Electronic Cigarette Use.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06177158 Not yet recruiting - Clinical trials for Electronic Cigarette Use

Efficacy of Oral Hygiene Instructions on Proinflammatory Cytokines Among Cigarette Smokers and Individuals Vaping Electronic Cigarettes During Plaque Induced Gingivitis (Clinical Trial)

Start date: December 20, 2023
Phase: N/A
Study type: Interventional

To evaluate the level of proinflammatory cytokines in individual vaping electronic cigarette in gingivitis patients. Can vaping affects the proinflammatory cytokines level in diseased individuals? Group I: cigarette smoker with gingivitis. Group II: electronic cigarette smoker with gingivitis. Group III: non-smoker with gingivitis. participants will be asked to perform oral hygiene instructions. measurement of inflammatory biomarkers MMP8 and MMP9 base line and after intervention will be done.

NCT ID: NCT06063421 Not yet recruiting - Smoking Cessation Clinical Trials

Comparison of Nicotine Replacement Therapy and Electronic Cigarettes for Smoking Cessation in Pakistan

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

Smoking is prevalent in Pakistan, and a large proportion of the adult population smokes cigarettes or uses other forms of tobacco. Smoking cessation programmes are not well established, and the few centres that offer cessation, only provide basic support without stop-smoking medicines or other aids that can help people quit. Internationally approved stop-smoking treatments like nicotine replacement therapy (NRT) are available in larger cities, but they are very expensive. This makes it difficult for the general population to use NRT to aid in their desire to quit smoking. In the past few years, the use of electronic cigarettes (EC) has increased manifold. These devices are freely available and are offered in a wide variety of types and flavours. EC are also cheaper compared to NRT, which makes them affordable for most smokers. EC are not considered smoking cessation tools and are not used or recommended by cessation services. This study wants to compare EC with NRT to see which treatment is more successful in helping people quit smoking. The premise is that EC are more effective than NRT. The study also wants to determine the cost of using EC compared to that of NRT, when used for quitting smoking. The study will have a total of 438 participants who will be assigned randomly (by chance) to two groups: NRT and EC. 219 participants will be provided with NRT, and 219 with EC. The participants will be adult smokers presenting at designated smoking cessation centres who are seeking help in quitting smoking. The main focus of the study is to see if EC are more successful than NRT in helping people quit smoking at the end of one year. This research will provide useful information on the effectiveness and safety of EC and help develop a smoking cessation policy tailored to the population of Pakistan.

NCT ID: NCT05881304 Not yet recruiting - Clinical trials for Electronic Cigarette Use

Switching Individuals in Treatment for Opioid Use Disorder Who Smoke Cigarettes to the SREC

SWITCHED
Start date: July 1, 2024
Phase: N/A
Study type: Interventional

The goal of this study is to conduct a pilot randomized waitlist-controlled trial to assess the feasibility, acceptability, and preliminary effects of substituting the NIDA standardized research e-cigarette (SREC) for combusted cigarettes in MOUD-TUD who are not ready to quit smoking. A waitlist controlled RCT using a mixed-methods sequential explanatory design will investigate the impact of SREC provision on: 1) tobacco use behavior (e.g., cigarettes per day [primary outcome], SREC use), 2) biomarkers (e.g., carbon monoxide, anabasine), 3) cigarette dependence and withdrawal, and 4) short-term health effects and tolerability (e.g., respiratory symptoms, substance use). In the proposed RCT, N=40 adults stable on MOUD with buprenorphine who report daily smoking recruited from MGH primary care practices will be randomly assigned to receive the SREC for 8 weeks, either immediately (iSREC), or after an 8-week delay (waitlist control [WLC]). They will be followed an additional 4 weeks after SREC provision ends (to 12 weeks in iSREC and 20 weeks in WLC).